Literature DB >> 24650055

The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.

Ahmet Emre Eskazan1, Tugrul Elverdi, Fevzi Firat Yalniz, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24650055     DOI： 10.3109/10428194.2014.905774

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293).

Authors:  Ahmet Emre Eskazan; Teoman Soysal
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

2.  Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Authors:  Iman Abou Dalle; Hagop Kantarjian; Jan Burger; Zeev Estrov; Maro Ohanian; Srdan Verstovsek; Farhad Ravandi; Gautam Borthakur; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Journal:  Cancer Med       Date:  2019-09-10       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.